Acerta Pharma B.V. et al v. Cipla Limited et al
| Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca AB and AstraZeneca Pharmaceuticals LP |
| Cipla Limited and Cipla USA, Inc. |
| 1:2024cv00587 |
| May 16, 2024 |
| US District Court for the District of Delaware |
| Gregory B Williams |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 1 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on May 22, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 9 WAIVER OF SERVICE returned executed by AstraZeneca UK Limited, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca AB: For Cipla Limited waiver sent on 5/22/2024, answer due 7/22/2024. (Silver, Daniel) |
| Filing 8 WAIVER OF SERVICE returned executed by AstraZeneca UK Limited, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca AB: For Cipla USA, Inc. waiver sent on 5/22/2024, answer due 7/22/2024. (Silver, Daniel) |
| Filing 7 Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 4, 2024. Date of Expiration of Patent: January 21, 2035 (10,272,083), July 1, 2036 (11,059,829).Thirty Month Stay Deadline: 10/4/2026. (Silver, Daniel) |
| Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) |
| Filing 6 Summons Issued as to Cipla Limited on 5/16/2024; Cipla USA, Inc. on 5/16/2024. (Attachments: #1 Summons Issued)(oam) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (oam) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,272,083; 11,059,829. (oam) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 04/24/24. Date of Expiration of Patent: 01/21/35 and 07/01/2036Thirty Month Stay Deadline: No earlier than 10/26/2026. (oam) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Cipla Limited, Cipla USA, Inc. ( Filing fee $ 405, receipt number ADEDC-4408798.) - filed by AstraZeneca UK Limited, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca AB. (Attachments: #1 Exhibit A-B, #2 Civil Cover Sheet)(oam) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
